Business Wire

Engle Martin & Associates, LLC Announces Acquisition of EIMC, LLC

17.4.2023 15:00:00 EEST | Business Wire | Press release

Share

Engle Martin & Associates, LLC ("Engle Martin"), a market-leading independent loss adjusting and claims management provider, announced today that it has acquired EIMC, LLC (“EIMC”), a leading global provider of ocean marine, risk management, claims investigation, and subrogation services based in Jersey City, New Jersey and London, England.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230417005197/en/

Founded in 1968, EIMC serves clients across the entire marine global supply chain with 50+ years of expertise in providing the full continuum of assessments, risk mitigation, and claim resolution solutions within marine cargo, stock throughout, hull & machinery, and fine art & specie. EIMC operates in 15 office locations strategically positioned in the United States and the United Kingdom. The organization works with a broad group of clients in all major international insurance markets and is also the Lloyd’s Agent for multiple locations in the United States. Since its inception, EIMC has been recognized by major international insurers and numerous insurance associations as a premier provider of marine insurance risk management and claims services.

This acquisition expands Engle Martin’s global footprint and diversifies its service portfolio by providing clients with a full suite of ocean marine services. This acquisition also provides EIMC an extensive back-office infrastructure, innovative technology solutions, and growth opportunities for team members. EIMC has a remarkable history within the maritime community that has resulted in distinctive and long-lasting relationships with its clients and carrier partners. EIMC’s leadership team will remain in place and will maintain operational oversight of their portfolio.

When asked about the acquisition, Jay Campbell, Executive Vice President of Strategy & Organizational Growth of Engle Martin, said “We are excited to continue growing and investing in our business. The acquisition expands our service capabilities in the ocean marine & technical risk services arena with an organization that is well-aligned with our culture and approach to business. We will continue to provide our clients with the same service, quality, and capabilities they have come to expect from our team, with a complementary service that allows us to respond to our customers in a holistic manner.”

Tiina Ruhlandt, Managing Director of EIMC, said “We are delighted that Engle Martin appreciates the value of our organization; and we are confident and excited that our combined expertise will have a positive impact on our continued growth and success. We believe that this partnership is an excellent extension of Engle Martin’s long-term business strategy, and we are thrilled to have a partner who shares our principles and respects the culture which has driven our success.”

About Engle Martin

Engle Martin is a market-leading independent loss adjusting and claims management provider. Engle Martin has a comprehensive business philosophy: to provide the best insurance claim adjustment results in the industry, present the most talented claims professionals, foster an innovative and professional leadership team, and develop client-focused solutions. The firm provides a comprehensive line of service offerings including commercial property, casualty, specialty marine and transportation, appraisal/umpire, specialty audits, carrier outsourcing, and claims management services. For details about industries served and services offered by Engle Martin, visit EngleMartin.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dominique Enriquez
Marketing Director
+1 678.553.3872
denriquez@englemartin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye